Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors

Published:2024-05-17 Issue:11-12 Volume:16 Page:799-807
ISSN:1750-1911
Container-title:Epigenomics
language:en
Short-container-title:Epigenomics

Author:

Lee Min Kyung¹^ORCID,Zhang Ze¹^ORCID,Sehgal Kartik²^ORCID,Butler Rondi³⁴^ORCID,Stolrow Hannah¹^ORCID,Ramush Geat³⁴,Shirai Keisuke⁵^ORCID,Koestler Devin C⁶^ORCID,Salas Lucas A¹^ORCID,Wiencke John K⁷^ORCID,Haddad Robert²^ORCID,Kelsey Karl T³⁴^ORCID,Christensen Brock C¹⁸⁹^ORCID

Affiliation:

1. Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755, USA

2. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA

3. Department of Epidemiology, Brown University School of Public Health, Providence, RI 02903, USA

4. Department of Pathology & Laboratory Medicine, Brown University School of Medicine, Providence, RI 02903, USA

5. Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03766, USA

6. Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS 66103, USA

7. Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA

8. Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755,USA

9. Department of Community & Family Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755, USA

Funder

National Cancer Institute

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17501911.2024.2343274

Reference37 articles.

1. Cancer statistics, 2022

2. SEER Cancer Statistics Review, 1975–2018 [Internet];Howlander N;National Cancer Institute.,2021

3. Epidemiology of Head and Neck Cancer

4. Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume

5. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study